| |
|
|
|
Publications by the CF Referral Center Team
Zhou J, Chen Y, Tabibi S, Alba L, Garber E and Saiman L. Antimicrobial susceptibility and synergy studies of Burkholderia cepacia complex isolated from patients with cystic fibrosis. Antimicrob Agents Chemother 2007;41:1085-1088.
Zhou J, Garber E, Desai M, and Saiman L. Compliance of clinical microbiology laboratories in the United States with current recommendations for processing respiratory tract specimens from patients with cystic fibrosis. J Clin Micro 2006;44:1547-1549.
Chen Y, Garber E, Zhao Q, Ge Y, Wikler M, Kaniga K, Saiman L. In vitro activity of doripenem (S-4661) against multidrug-resistant gram negative bacilli isolated from patients with cystic fibrosis. Antimicrob Agents Chemother 2005; 49: 2510-2511.
San Gabriel P, Zhou J, Tabibi S, Chen Y, Trauzzi M, Saiman L. Antimicrobial susceptibility and synergy studies of Stenotrophomonas maltophilia isolated from patients with cystic fibrosis. Antimicrob Agents Chemother 2004;48:168-71.
Saiman L, Burns JL, Larone D, Chen Y, Garber E, Whittier S. Evaluation of microscan autoscan for the identification of Pseudomonas aeruginosa from cystic fibrosis patients. J Clin Micro 2003;41:492-4.
Saiman L, Siegel J, the CF Foundation Consensus Conference on Infection Control Participants. Infection control recommendations for patients with cystic fibrosis: microbiology, important pathogens, and infection control practices to prevent patient-to-patient transmission. Infect Control Hosp Epid 2003;24(Suppl 5):S1-52. Am J Infect Control 2003;31(Suppl 3):S1-62.
Saiman L, San Gabriel P, Knirsch C. Synergistic activities of macrolide antibiotics against Pseudomonas aeruginosa, Burkholderia cepacia, Stenotrophomonas maltophilia and Alcaligenes xylosoxidans isolatedfrom patients with cystic fibrosis. Antimicrob Agents Chemother 2002;46:1105-7.
Burns JL, Saiman L, Whittier S, Krzewinski J, Liu Z, Larone D, Jones RN. Comparison of two commercial systems (Vitek and Microscan-WalkAway) for antimicrobial susceptibility testing of Pseudomonas aeruginosa isolates from cystic fibrosis patients. Diagn Microbiol Infect Dis 2001;39:257-60.
Saiman L, Chen Y, Tabibi S, San Gabriel P, Zhou J, Liu Z, Lai L, Whittier S. Identification and antimicrobial susceptibility testing of Alcaliagenes xylosoxidans isolated from patients with cystic fibrosis. J Clin Micro 2001;39:3942-5.
Burns JL, Saiman L, Whittier S, Larone D, Krzewinski J, Liu Z, Marshall S, Jones RN. Comparison of agar diffusion methodologies for antimicrobial susceptibility testing of Pseudomonas aeruginosa isolates from cystic fibrosis patients. J Clin Microbiol 2000;38:1818-22.
Saiman L, Burns JL, Whittier S, Krzewinski S, Marshall SA, Jones RA. Evaluation of reference dilution test methods for antimicrobial susceptibility testing of Pseudomonas aeruginosa isolated from patients with cystic fibrosis. J Clin Microbiol 1999;37:2987-91.
Saiman L, Mehar F, Niu WW, Neu HC, Shaw KJ, Miller G, Prince A. Antibiotic susceptibility of multiply resistant Pseudomonas aeruginosa isolated from patients with cystic fibrosis, including candidates for transplantation. Clin Infect Dis 1996;23:532-7.
|
|
|
The information provided in this site is intended only for CF caregivers in the United States. The information, procedures and materials discussed herein may have different product labeling in different countries.
Copyright © 2008 Cystic Fibrosis Foundation. All rights reserved
For corrections and/or comments about this web site, please send an email to la2131@columbia.edu. |
|
| |
|
.png){kind=logo}
